交易中 10-07 11:43:41 美东时间
+0.065
+1.04%
今日重点评级关注:HC Wainwright & Co.:维持NeuroSense Therapeutics"买入"评级,目标价从8美元升至52美元;HC Wainwright & Co.:维持艾切托"买入"评级,目标价从27美元升至34美元
09-29 08:33
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phas...
09-26 04:01
今日重点评级关注:康托·菲茨杰拉德:维持Abeona Therapeutics"超配"评级,目标价从28美元升至30美元;HC Wainwright & Co.:维持Oculis Holding"买入"评级,目标价从26美元升至39美元
09-21 16:25
HC Wainwright & Co. analyst Robert Burns reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $27 price target.
09-19 00:42
Adicet Bio ( ($ACET) ) has provided an update. On September 8, 2026, Adicet Bio...
09-09 05:16
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cle...
08-28 04:02
今日重点评级关注:康托·菲茨杰拉德:维持EyePoint"超配"评级,目标价从47美元升至55美元;伯恩斯坦:维持Figure Technology"跑赢大市"评级,目标价从67美元升至70美元
08-07 13:41
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.
08-06 21:51
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the same period last year.
08-06 06:08